Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05508867 · ClinicalTrials.gov registry record · Phase 2
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
A Phase 2 study of Hodgkin Lymphoma, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 203
- Enrollment target
- 20
- Study locations
NCT05508867: Completed Phase 2 study of Hodgkin Lymphoma, sponsored by Merck Sharp & Dohme.
NCT05508867 is a Phase 2 study of Hodgkin Lymphoma that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 203 participants, above the 163-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (25% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05508867, a Phase 2 study of Hodgkin Lymphoma, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 203 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth). Researchers want to learn if people who receive coformulated favezelimab/pembrolizumab (MK-4280A) live longer without the cancer getting worse compared to those who receive chemotherapy.
Primary Outcome
PFS was defined as the time from randomization to the first documented disease progression per Lugano criteria 2014 as assessed by investigator or death due to any cause, whichever occurred first. Progressive disease was defined as uptake moderately or markedly higher than the liver with an increase in overall uptake compared with nadir, and/or the appearance of new lesions consistent with lymphoma.
Conditions Studied
Interventions
- DRUG gemcitabine
- DRUG bendamustine
- BIOLOGICAL favezelimab/pembrolizumab
Study Locations (20)
California
- UCLA Hematology/Oncology - Santa Monica ( Site 2208) - Los Angeles
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site - Torrance
Maryland
- University of Maryland-Greenebaum Comprehensive Cancer Center ( Site 2210) - Baltimore
- Johns Hopkins University-The Sidney Kimmel Comprehensive Cancer Center ( Site 2206) - Baltimore
Michigan
- University of Michigan ( Site 2215) - Ann Arbor
- Cancer and Hematology Centers of Western Michigan ( Site 2222) - Grand Rapids
Ohio
- University Hospitals Cleveland Medical Center ( Site 2214) - Cleveland
- Cleveland Clinic-Taussig Cancer Center ( Site 2203) - Cleveland
Pennsylvania
- AHN West Penn Hospital ( Site 2213) - Pittsburgh
- UPMC Hillman Cancer Center ( Site 2205) - Pittsburgh
Other
- Hospital Aleman-oncohematologic diseases ( Site 2302) - Buenos Aires
- Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 2301) - Mendoza
Arizona
- The University of Arizona Cancer Center - North Campus ( Site 2216) - Tucson
Florida
- Moffitt Cancer Center ( Site 2200) - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2022-10-18 |
| Est. Completion | 2026-01-08 |
| Phase | Phase 2 |
What the finished NCT05508867 record still lists
NCT05508867 is an interventional study that assigns participants to a tested intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap, above the 163-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (25% higher).
The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which gemcitabine is the first listed.
NCT05508867 names 20 study sites across 14 states, led by California, Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT05508867 about?
NCT05508867 is a clinical study titled "A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)". Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth). Researchers want to learn if people who receive coformulated favezelimab/pembro...
What is the current status of trial NCT05508867?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 203 participants. The study started on 2022-10-18. Estimated completion is 2026-01-08.
What conditions does trial NCT05508867 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma.
What interventions are being tested in trial NCT05508867?
The interventions under investigation include: gemcitabine (DRUG), bendamustine (DRUG), favezelimab/pembrolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05508867?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05508867 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05508867's enrollment target sits among peer trials
203 13th of 71 higher than 59 of 71 other Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
RECRUITING · Phase 2
-
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RECRUITING · Phase 2
-
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
RECRUITING · Phase 2
-
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05652686 · 203 participants · Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NCT06063122 · 203 participants · NA
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
- NCT07031245 · 203 participants · NA
Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI